Vis børsmeldingen
expansion.
“We remain fully focused on growth in Sweden, our UK establishment, and further
development of our system for gastrointestinal diagnostics,” says CEO Fredrik
Palm, CEO of Inify Laboratories.
Sales in the first quarter amounted to SEK 5.1 million (2.2), representing 130%
growth compared to the same period in 2024. Cash balance at the end of the
quarter amounted to SEK 151.1 million, strengthened by the SEK 150 million share
issue completed in February.
“Our laboratory operations continue to generate positive financial results, with
further improvement expected as sample volumes grow,” says Palm.
During the first quarter, Inify established its initial UK organisation by
recruiting key personnel for subsidiary management, laboratory operations, and
sales. Planning for the laboratory construction is progressing well, and the
company has selecting a modern, newly built property in a business park just
south of Oxford.
“In parallel with the laboratory establishment, we have an ongoing, close
dialogue with public (NHS) and private healthcare providers - our future
customers,” said Palm.
Together with its customers, Inify has begun developing new, structured
processes in prostate cancer diagnostics, delivering superior efficiency and
quality.
“We are one quarter into what promises to be a very exciting year. Inify is
growing in Sweden, expanding internationally, and at the same time developing
new capabilities to broaden our service offering into gastrointestinal
diagnostics. In short, we are at the forefront of setting a new standard,” Palm
concludes.
For further information, please contact CEO Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com
The future of pathology
Inify Laboratories provides cancer diagnostics through ultramodern laboratory
services within pathology. It uses a fully digital, standardised and AI
-supported workflow to optimise quality and response times, initially within
prostate cancer.The concept is scalable and can be extended to other diagnoses.
The service includes the whole chain of sample handling: from logistics, to
sample preparation, to reporting by a pathologist. The report is assisted by our
own AI, proven in clinical studies to have world-leading accuracy. The complete
workflow is supported by a tailor-made process control system.
The company, based in Sweden, became independent in 2022 through a spin-off
fromContextVision (https://www.contextvision.com/), with 40 years of experience
within digital imaging for medical applications. Its shares are listed
onEuronext Growth Oslo under the ticker
INIFY (INIFY LABORATORIES | SE0017486103 | Euronext exchange Live quotes).
Kilde
